Revenue Performance - The company's revenue from Choline Phosphate reached ¥383,467,775.06, with a gross margin of 85.67%, representing a year-on-year increase of 19.70%[4] - Revenue from Eastern Stomach Medicine was ¥9,852,934.85, with a gross margin of 58.89%, showing a decrease compared to the previous year's 47.48%[4] - Revenue from other pharmaceuticals decreased to ¥29,869,674.55, with a gross margin of 22.61%, reflecting a year-on-year decline of 21.09%[8] Customer Concentration - Total sales to major customers amounted to ¥264,971,347.35, accounting for 62.47% of the annual sales, with the largest customer being China National Pharmaceutical Group, contributing ¥123,793,246.63 or 29.19%[10] - The report indicates a significant reliance on a few major customers, with the top three customers accounting for over 50% of total sales[10] Financial Corrections - The company acknowledged the correction of financial data in its 2021 annual report, ensuring the accuracy and completeness of the information disclosed[2] - The company expressed apologies for any inconvenience caused to investors due to the corrections made in the financial report[10] Operational Insights - The company reported a total operating cost of ¥54,962,314.74 for Choline Phosphate, resulting in a gross profit of ¥328,505,460.32[4] - The company plans to maintain its current strategies while addressing the discrepancies found in the previous report[2] - The overall financial performance indicates a mixed trend, with some products showing growth while others experienced declines in revenue and gross margin[4]
梓橦宫(832566) - 2021 Q4 - 年度财报(更正)